CBT vs LIN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CBT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CBT and LIN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CBT and LIN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cabot Corporation, based in Boston and founded in 1882, makes the black powder that gives tires their strength and wear resistance. Carbon black is mostly sold through its Reinforcement Materials segment to tire makers such as Michelin, Bridgestone and Goodyear, and that segment produced roughly $599 million of the ~$982 million in sales in the June 2026 quarter. The second segment, Performance Chemicals, sells specialty carbons for plastics and coatings, fumed silica and alumina, inkjet colorants and conductive additives for lithium-ion batteries. Cabot sold its activated carbon (Purification Solutions) unit in 2024 to concentrate on these two businesses, and it runs a global network of plants across the Americas, Europe and Asia, including new capacity in Indonesia and a Mexican carbon black producer bought in early 2026.

Full CBT guide

Linde is the largest industrial gases company in the world, providing oxygen, nitrogen, argon, hydrogen, helium, and various specialty gases to customers across manufacturing, healthcare, energy, electronics, and food processing. The company was formed in 2018 through the merger of Linde AG (German) and Praxair (US-based), making it dual-listed but primarily reporting in USD with a Connecticut headquarters.

Full LIN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CBT drivers: Tire contract pricing and volume recovery; Battery materials and conductive additives.
• LIN drivers: Long-term take-or-pay contract durability; Hydrogen and clean energy transition.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The biggest risk is that tire pricing keeps resetting lower. For LIN, capital intensity is meaningful for new gas plants, and free cash flow over the trailing twelve months was about $4.2 billion against operating cash flow of about $10.5 billion, so a large share of cash goes back into projects.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CBT if you believe its drivers more; LIN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CBT and LIN guides.

CBT. Figures are approximate and tied to the asOf date; verify live numbers before acting. Fiscal 2026 ended September 30 and full-year results are expected in early November 2026, so trailing figures will shift soon. GAAP earnings look far weaker than adjusted earnings this year because of restructuring and benefit plan charges, including a ~$1.55 per share hit in the June quarter. At roughly 12x adjusted earnings the stock trades near specialty chemical peers' low end, and the average analyst target of ~$89 to $91 sits well above the ~$74 quote, after the shares slid from the mid-$80s in August.

LIN. Linde trades at one of the highest valuations among industrial companies, about 32 times trailing earnings and 6.5 times sales, which rests on the durable contract structure, the demonstrated operational excellence, and the hydrogen and electronics growth story. With the stock near $498 on October 16, 2026 and up about 16% this year, the analyst mean target of about $544 sits roughly 9% above the price. The multiple has expanded over the past decade as the quality of the business model has been recognized.

Headline figures (approximate, October 2026): CBT shows revenue (ttm) ~$3.6 billion (June 2026 quarter ~$982 million, up ~6% year over year), adjusted eps (fy2026 guidance) ~$6.15 to $6.45 vs $7.25 in FY2025; June quarter ~$1.67, segment ebit (june 2026 quarter) Reinforcement Materials ~$97 million (down ~24%); Performance Chemicals ~$68 million (up ~19%), p/e (adjusted, forward) ~12x on FY2026 guidance at a share price near ~$74; LIN shows revenue (ttm) ~$35.5 billion, revenue growth (q2 2026, yoy) ~9%, operating margin ~28%, net income (ttm) ~$7.2 billion.

CBT and LIN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CBT and LIN exposure against your real portfolio. It is not an investment adviser.